The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Clinical impact of selective and nonselective beta‐blockers on survival in patients with ovarian cancer
Open accessAbstract
BACKGROUND: Preclinical evidence has suggested that sustained adrenergic activation can promote ovarian cancer growth and metastasis. The authors examined the impact of beta‐adrenergic blockade on the clinical outcome of women with epithelial ovarian, primary peritoneal, or fallopian tube cancers (collectively, epithelial ovarian cancer [EOC]). METHODS: A multicenter review of 1425 women with histopathologically confirmed EOC was performed. Comparisons were made between patients with documented beta‐blocker use during chemotherapy and those without beta‐blocker use. RESULTS: The median age of patients in the current study was 63 years (range, 21‐93 years). The sample included 269 patients who received beta‐blockers. Of those, 193 (71.7%) were receiving beta‐1–adrenergic receptor selective agents, and the remaining patients were receiving nonselective beta antagonists. The primary indication for beta‐blocker use was hypertension but also included arrhythmia and postmyocardial infarction management. For patients receiving any beta‐blocker, the median overall survival (OS) was 47.8 months versus 42 months for nonusers (P =.04). The median OS based on beta‐blocker receptor selectivity was 94.9 months for those receiving nonselective beta‐blockers versus 38 months for those receiving beta‐1–adrenergic receptor selective agents (P<.001). Hypertension was associated with decreased OS compared with no hypertension across all groups. However, even among patients with hypertension, a longer median OS was observed among users of a nonselective beta‐blocker compared with nonusers (38.2 months vs 90 months; P<.001). CONCLUSIONS: Use of nonselective beta‐blockers in patients with EOC was associated with longer OS. These findings may have implications for new therapeutic approaches. Cancer 2015;121:3435–43. © 2015 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma
Thaker, P. H., Han, L. Y., Kamat, A. A., Arevalo, J. M., Takahashi, R., Lu, C., Jennings, N. B., Armaiz-Pena, G., Bankson, J. A., Ravoori, M., et al. (2006) · Nature Medicine · doi:10.1038/nm1447 · Cited by 1,320 · cited 1×
“Tumors in these stressed animals demonstrated increased vascularization and enhanced expression of vascular endothelial growth factor, MMP-2, and MMP-9, effects that could be reversed by propranolol.(3) This extensive preclinical evidence that adrenergic signaling promotes the growth of ovarian cancer, combined with s…”
BackgroundSelf-citationThe sympathetic nervous system induces a metastatic switch in primary breast cancer
Sloan, E. K., Priceman, S. J., Cox, B. F., Yu, S., Pimentel, M. A., Tangkanangnukul, V., Arevalo, J. M. G., Morizono, K., Karanikolas, B. D. W., Wu, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0522 · Cited by 930
Self-citationAdrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis
Sood, A. K., Armaiz-Pena, G. N., Halder, J., Nick, A. M., Stone, R. L., Hu, W., Carroll, A. R., Spannuth, W. A., Deavers, M. T., Allen, J. K., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40802 · Cited by 283 · cited 1×
“In vitro studies have shown that it is specifically ADRB2 stimulation that contributes to ovarian cancer development and metastasis.(2-4,13) This is supported by the improvements in OS noted among patients receiving NSBB compared with those taking any betablocker.”
BackgroundSelf-citationBeta‐blockers may reduce intrusive thoughts in newly diagnosed cancer patients
Lindgren, M. E., Fagundes, C. P., Alfano, C. M., Povoski, S. P., Agnese, D. M., Arnold, M. W., Farrar, W. B., Yee, L. D., Carson, W. E., Schmidt, C. R., et al. (2013) · Psycho-Oncology · doi:10.1002/pon.3233 · Cited by 35
Cited by
The updated landscape of tumor microenvironment and drug repurposing
Jin, M.-Z., & Jin, W.-L. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00280-x · Cited by 1,262
Neuroimmune Interactions: From the Brain to the Immune System and Vice Versa
Dantzer, R. (2018) · Physiological Reviews · doi:10.1152/physrev.00039.2016 · Cited by 1,073
Sympathetic nervous system regulation of the tumour microenvironment
Cole, S. W., Nagaraja, A. S., Lutgendorf, S. K., Green, P. A., & Sood, A. K. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3978 · Cited by 576
Self-citationβ2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer
Renz, B. W., Takahashi, R., Tanaka, T., Macchini, M., Hayakawa, Y., Dantes, Z., Maurer, H. C., Chen, X., Jiang, Z., Westphalen, C. B., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.11.007 · Cited by 543
Bucsek, M. J., Qiao, G., MacDonald, C. R., Giridharan, T., Evans, L., Niedzwecki, B., Liu, H., Kokolus, K. M., Eng, J. W.-L., Messmer, M. N., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0546 · Cited by 294
Nerve Dependence: From Regeneration to Cancer
Boilly, B., Faulkner, S., Jobling, P., & Hondermarck, H. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.005 · Cited by 290
Tumor Neurobiology and the War of Nerves in Cancer
Faulkner, S., Jobling, P., March, B., Jiang, C. C., & Hondermarck, H. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1398 · Cited by 267
Kokolus, K. M., Zhang, Y., Sivik, J. M., Schmeck, C., Zhu, J., Repasky, E. A., Drabick, J. J., & Schell, T. D. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1405205 · Cited by 200
β-blockers: Their new life from hypertension to cancer and migraine
Fumagalli, C., Maurizi, N., Marchionni, N., & Fornasari, D. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104587 · Cited by 102
Sorski, L., Melamed, R., Matzner, P., Lavon, H., Shaashua, L., Rosenne, E., & Ben-Eliyahu, S. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.05.017 · Cited by 85
Long, Q., Zheng, H., Liu, X., & Guo, S.-W. (2019) · Reproductive Sciences · doi:10.1177/1933719119828066 · Cited by 16
Metadata
- Authors
- Watkins, J. L., Thaker, P. H., Nick, A. M., Ramondetta, L. M., Kumar, S., Urbauer, D. L., Matsuo, K., Squires, K. C., Coleman, R. L., Lutgendorf, S. K., Ramirez, P. T., & Sood, A. K.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2015-08-24
- Volume
- 121
- Issue
- 19
- Pages
- 3444-3451
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1947924801
- Cited by
- 196
- References
- 4
- FWCI
- 16.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.